LTF and COVID-19: Clinical trials are currently ongoing to assess the efficacy of inhalable anti-COVID-19 nanoformulations, such as remdesivir NPs and liposomal lactoferrin (Clinical Trial # NCT04480333 and # NCT04475120) [150].